| CASE REPORT |
|
| Year : 2020 | Volume
: 38
| Issue : 1 | Page : 55-58 |
|
|
Bullous lichen planus-like reactions in a patient with renal cancer after receiving anti-programmed cell death-1 therapy
Hua-Ching Chang1, Yin-Shuo Chang1, Hsin-Lun Lee2, Ming-Hsiu Lin3
1 Department of Dermatology, Taipei Medical University Hospital, Taipei, Taiwan
2 Department of Radiation Oncology, Taipei Medical University Hospital, Taipei, Taiwan
3 Department of Dermatology; Department of Dermatology, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan
Correspondence Address:
Ming-Hsiu Lin
Department of Dermatology, Taipei Medical University Hospital, Taipei, Taiwan, No. 252, Wuxing St, Xinyi District, Taipei City, 110
Taiwan
 Source of Support: None, Conflict of Interest: None  | 2 |
DOI: 10.4103/ds.ds_17_19
|
|
|
Anti-programmed cell death 1 (anti-PD-1) agent is a promise in cancer immunotherapy for various advanced malignancies, but dermatologic toxicities are common during therapy. We report one advanced transitional cell carcinoma patient who developed multiple bullous skin lesions over bilateral lower extremities after anti-PD-1 antibody pembrolizumab treatment. Skin biopsy revealed subepidermal cleft, wedge-shaped hypergranulosis, saw-tooth acanthosis, and presence of interface band-like lymphohistiocytic infiltrate compatible with bullous lichen planus-like reactions. Potent topical steroid and temporary cessation of pembrolizumab relieved the skin eruptions. Early recognition and appropriate management of rare bullous dermatologic toxicities are critical in patients receiving immune checkpoint blockade therapy.
|
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
